About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Hspa13tm1.1Smoc
targeted mutation 1.1, Shanghai Model Organisms Center
MGI:6694146
Summary 2 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * 129S * C57BL/6 MGI:6694201
cn2
 		Faslpr/Faslpr
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp MGI:6694199


Genotype
MGI:6694201
cn1
Allelic
Composition		 Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * 129S * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (56 available)
Hspa13tm1.1Smoc mutation (0 available); any Hspa13 mutation (20 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
decreased plasma cell number ( J:303927 )
• reduced TACI+CD138+B220-CD19int early cells and TACI+CD138+B220-CD19- mature cells in the spleen, lymph nodes and bone marrow
• reduced LPS-induced TACI+CD138+B220-CD19int early plasma cells and TACI+CD138+B220-CD19- mature plasma cells
• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasma cells
abnormal plasmablast number ( J:303927 )
• decreased TACI+CD138+B220intCD19int cells
• decreased plasmablasts in LPS-treated mice
• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasmablasts
abnormal humoral immune response ( J:303927 )
• mice treated with NP-Ficoll and NP-KLH exhibit reduced NP-specific IgM, IgG, IgG1, IgG2b, IgG2c, IgG3, IgA, and IgE antibodies
decreased IgA level ( J:303927 )
• at baseline
decreased IgE level ( J:303927 )
• at baseline
decreased IgG level ( J:303927 )
• at baseline or mice treated with sheep red blood cells
decreased IgG1 level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG2b level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG2c level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG3 level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgM level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased autoantibody level ( J:303927 )
• in mice treated with pristane compared with similarly treated control mice

renal/urinary system
increased urine protein level ( J:303927 )
• in mice treated with pristane that is not as high as in control mice

homeostasis/metabolism
increased urine protein level ( J:303927 )
• in mice treated with pristane that is not as high as in control mice
decreased susceptibility to injury ( J:303927 )
• mice treated with hydrocarbon oil 2, 6, 10, 14-tetramethylpentadecane (TMPD or pristane) to induce systemic lupus erythematosus exhibit reduced increase in autoantibody levels and proteinuria compared with control mice

hematopoietic system
decreased plasma cell number ( J:303927 )
• reduced TACI+CD138+B220-CD19int early cells and TACI+CD138+B220-CD19- mature cells in the spleen, lymph nodes and bone marrow
• reduced LPS-induced TACI+CD138+B220-CD19int early plasma cells and TACI+CD138+B220-CD19- mature plasma cells
• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasma cells
abnormal plasmablast number ( J:303927 )
• decreased TACI+CD138+B220intCD19int cells
• decreased plasmablasts in LPS-treated mice
• decreased sheep red blood cell induced IgG1-, Ig2b-, IgG2c-, and IgG3 expressing plasmablasts
decreased IgA level ( J:303927 )
• at baseline
decreased IgE level ( J:303927 )
• at baseline
decreased IgG level ( J:303927 )
• at baseline or mice treated with sheep red blood cells
decreased IgG1 level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG2b level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG2c level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgG3 level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice
decreased IgM level ( J:303927 )
• at baseline and in LPS- or sheep red blood cell-treated mice




Genotype
MGI:6694199
cn2
Allelic
Composition		 Faslpr/Faslpr
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (56 available)
Faslpr mutation (39 available); any Fas mutation (82 available)
Hspa13tm1.1Smoc mutation (0 available); any Hspa13 mutation (20 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
decreased susceptibility to systemic lupus erythematosus ( J:303927 )
• mice exhibit reduced increase in autoantibody levels and proteinuria levels compared with control mice
decreased autoantibody level ( J:303927 )
• compared with Faslpr homozygotes

renal/urinary system
increased urine protein level ( J:303927 )
• not as severe as in Faslpr homozygotes

homeostasis/metabolism
increased urine protein level ( J:303927 )
• not as severe as in Faslpr homozygotes




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/30/2024
MGI 6.23 		The Jackson Laboratory